Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
betamethasone (betamethasone 17-valerate)
Schering-Plough Labo N.V.
D07AC01
betamethasone (betamethasone 17-valerate)
1mg/g
ointment
aluminium tube 30g
Prescription
Registered
2019-04-22
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT CELESTODERM-V ® 2. COMPOSITION 1 g of ointment contains _active substance:_ 1 mg betamethasone (as betamethasone 17-valerate 1.22 mg); _excipients:_ paraffin white liquid, mineral oil. 3. PHARMACEUTICAL FORM Ointment. _DESCRIPTION: _ soft white homogenous ointment, without foreign matters. PHARMACOTHERAPEUTIC GROUP Corticosteroids for dermatological use. Corticosteroids, potent (group III). АТС Code D07A C01. 4.1 THERAPEUTIC INDICATIONS Relief of the inflammatory manifestations of corticosteroid-responsive dermatoses such as: eczema (atopic, nummular), contact dermatitis, seborrheic dermatitis, neurodermatitis, solar dermatitis, exfoliative dermatitis, dermatitis due to radiation, intertrigo, psoriasis (excluding disseminated psoriasis). 4.2. DOSAGE AND ADMINISTRATION A thin film of Celestoderm-V ® should be applied to the affected area 1-3 times daily depending on severity of the condition. Application once or twice a day is often feasible and effective. Frequency of application should be determined according to severity of the condition. While mild cases may respond to once a day application, more severe cases may require more frequent application. Do not apply under occlusive dressings as it can potentiate adverse actions of medication. Continuous use of the medication should not exceed 4 weeks. After therapeutic effect is achieved frequency of Celestoderm-V ® should be decreased or less active topical corticosteroid should be used, and supportive therapy should be continued with gradual withdrawal of the medication. If clinical improvement is not achieved by two to four weeks, examination should be repeated, and treatment should be reviewed. 4.3 CONTRAINDICATIONS Untreated skin diseases induced by bacterial infections of the skin (e.g. pyogenic dermatitis, tuberculosis and syphilitic processes), viral infections of the skin (e.g. varicella, herpes simplex, herpes zoster, verrucas vulga, warts, molluscum contagiosum), fungal infections o Read the complete document